Vir Biotechnology (VIR)

Executive Summary

Vir Biotechnology is a San Francisco-based clinical-stage immunology company leveraging advanced antibody engineering and protease-releasable masking technology to develop transformative therapeutics for infectious diseases and oncology. The company has validated its rapid antibody discovery platform through COVID-19 (sotrovimab) and Ebola programs, and is now strategically focused on chronic hepatitis B and D, as well as select oncology indications. Its pipeline includes a Phase 2 combination therapy for hepatitis B (PEG-IFNα + BRII-835), which completed enrollment in February 2026, and a Phase 2 triple combination for hepatitis D (VIR-2218 + VIR-3434 + NRTI) with data expected in the coming months. In oncology, Vir is advancing early-stage programs such as VIR-5500 for prostate cancer and VIR-5525 in combination with pembrolizumab for solid tumors, both in Phase 1. Key upcoming catalysts include the release of Phase 2 data from the hepatitis B combo trial, which could demonstrate functional cure potential, and interim results from the hepatitis D program, a high-unmet-need indication with no approved therapies. Additionally, initial proof-of-concept data from the oncology pipeline may provide validation of the company's platform beyond infectious diseases. Vir's strong balance sheet and strategic partnerships (e.g., with Brii Biosciences) support its pipeline development, though near-term revenue remains dependent on partnership milestones. The stock is trading at a valuation that reflects significant pipeline risk but also upside from successful clinical readouts.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data for PEG-IFNα + BRII-835 in chronic hepatitis B60% success
• H2 2026Interim Phase 2 data for VIR-2218 + VIR-3434 + NRTI in hepatitis D50% success
• H1 2027Initial Phase 1 data for VIR-5500 in prostate cancer30% success